Gland Pharma Limited
Simbol: GLAND.NS
NSE
1688.1
INRTržna cena danes
42.3302
Razmerje P/E
-1.6054
Razmerje PEG
278.05B
Kapaciteta MRK
- 0.00%
Donos DIV
Gland Pharma Limited (GLAND-NS) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 38362 | 32427.2 | 24465 | |||||||
balance-sheet.row.short-term-investments | 0 | 19273 | 29268.9 | 19546.8 | |||||||
balance-sheet.row.net-receivables | 0 | 8715.3 | 12514.7 | 12726.8 | |||||||
balance-sheet.row.inventory | 0 | 19453 | 11856.7 | 12751.7 | |||||||
balance-sheet.row.other-current-assets | 0 | 2477.8 | 1722.3 | 1292.9 | |||||||
balance-sheet.row.total-current-assets | 0 | 69008.1 | 58520.8 | 51236.4 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 17361 | 17269 | 13244.4 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.long-term-investments | 0 | -733.7 | 2000 | -19477.3 | |||||||
balance-sheet.row.tax-assets | 0 | 958.9 | -415.1 | 0 | |||||||
balance-sheet.row.other-non-current-assets | 0 | 1064.4 | 836.1 | 19957.3 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 18767.3 | 19815.4 | 13724.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.account-payables | 0 | 5873.5 | 4628.5 | 4007.3 | |||||||
balance-sheet.row.short-term-debt | 0 | 7.1 | 2.6 | 3 | |||||||
balance-sheet.row.tax-payables | 0 | 9.8 | 179.8 | 286.9 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 37.4 | 44.8 | 47 | |||||||
Deferred Revenue Non Current | 0 | 49.9 | 55.5 | 56.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 924.7 | 552.6 | 63.3 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 896.8 | 939.8 | 803.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 6.3 | 8.1 | 9.3 | |||||||
balance-sheet.row.total-liab | 0 | 8188.1 | 6760 | 5928.4 | |||||||
balance-sheet.row.preferred-stock | 0 | 15.6 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 164.7 | 164.3 | 163.6 | |||||||
balance-sheet.row.retained-earnings | 0 | 60153.9 | 52343.4 | 40226.8 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -15.6 | 114.5 | 240.9 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 19268.6 | 18953.9 | 18401.1 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 0 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 18539.3 | 2000 | 69.5 | |||||||
balance-sheet.row.total-debt | 0 | 44.5 | 47.4 | 50 | |||||||
balance-sheet.row.net-debt | 0 | -19044.4 | -3110.8 | -4868.3 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 10545.8 | 16185.5 | 13348.1 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 1467.4 | 1103 | 987.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -4143.8 | -3254 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 46.2 | 155.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -4179.4 | -3930.8 | -4357.6 | |||||||
cash-flows.row.account-receivables | 0 | 1440 | -4195.7 | -602 | |||||||
cash-flows.row.inventory | 0 | -7596.3 | 895 | -5188.9 | |||||||
cash-flows.row.account-payables | 0 | 1209.8 | 658.5 | 1428.2 | |||||||
cash-flows.row.other-working-capital | 0 | 767.2 | -1288.6 | 5.1 | |||||||
cash-flows.row.other-non-cash-items | 0 | -4194.1 | -1352.4 | -830.4 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.acquisitions-net | 0 | -12705.6 | 6117.2 | 4.3 | |||||||
cash-flows.row.purchases-of-investments | 0 | -4699.8 | -16818.1 | -13575.9 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 17405.4 | 10700.9 | -4.3 | |||||||
cash-flows.row.other-investing-activites | 0 | 14313.1 | -4805 | 623.7 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 12081.9 | -10026.2 | -15240 | |||||||
cash-flows.row.debt-repayment | 0 | -1.1 | -1.4 | -8.9 | |||||||
cash-flows.row.common-stock-issued | 0 | 215 | 385.5 | 12418.1 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -64.7 | -35.2 | -24.6 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 149.2 | 349 | 12384.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 30 | 33.1 | 35.8 | |||||||
cash-flows.row.net-change-in-cash | 0 | 15900.8 | -1736.4 | 3229.7 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 19089 | 3188.2 | 4924.6 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3188.2 | 4924.6 | 1695 | |||||||
cash-flows.row.operating-cash-flow | 0 | 3639.7 | 7907.7 | 6049.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.free-cash-flow | 0 | 1408.5 | 2686.5 | 3761.5 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 36246 | 43841.4 | 34236.4 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 16854.3 | 21092.2 | 14918.7 | |||||||
income-statement-row.row.gross-profit | 0 | 19391.7 | 22749.3 | 19317.6 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.operating-expenses | 0 | 10611.5 | 8745.5 | 7280.4 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 27465.7 | 29837.7 | 22199.2 | |||||||
income-statement-row.row.interest-income | 0 | 1794.2 | 1386.5 | 859.5 | |||||||
income-statement-row.row.interest-expense | 0 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.interest-expense | 0 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1467.4 | 1103 | 987.8 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | 8844.4 | 14000.3 | 12034.5 | |||||||
income-statement-row.row.income-before-tax | 0 | 10545.8 | 16185.5 | 13348.1 | |||||||
income-statement-row.row.income-tax-expense | 0 | 2735.4 | 4068.9 | 3378.5 | |||||||
income-statement-row.row.net-income | 0 | 7810.4 | 12116.6 | 9969.6 |
Pogosto zastavljeno vprašanje
Kaj je Gland Pharma Limited (GLAND.NS) skupna sredstva?
Gland Pharma Limited (GLAND.NS) skupna sredstva so 87775350000.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so N/A.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.605.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je 35.155.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je 0.134.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so 0.189.
Kaj je Gland Pharma Limited (GLAND.NS) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je 7810430000.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 44530000.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 10611470000.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 0.000.